Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism.

Trial Profile

Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2016 Status changed from recruiting to discontinued because no participant enrolled for three years and no plan to continue study.
    • 21 Mar 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 21 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top